4 datasets found
  1. c

    covid 19 treatment Report

    • datainsightsmarket.com
    doc, pdf, ppt
    Updated Jan 7, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Data Insights Market (2025). covid 19 treatment Report [Dataset]. https://www.datainsightsmarket.com/reports/covid-19-treatment-1494332
    Explore at:
    ppt, doc, pdfAvailable download formats
    Dataset updated
    Jan 7, 2025
    Dataset authored and provided by
    Data Insights Market
    License

    https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    CA
    Variables measured
    Market Size
    Description

    The global COVID-19 treatment market, valued at USD 59.2 million in 2025, is projected to reach USD 329.1 million by 2033, exhibiting a CAGR of 25.1% during the forecast period. The significant growth can be attributed to the rising prevalence of COVID-19, increasing government initiatives, and ongoing research and development activities in the development of novel treatments. Additionally, the growing demand for antiviral drugs and monoclonal antibodies, as well as supportive therapies, is further fueling market growth. The market is highly competitive, with prominent players such as Cadila Healthcare, Johnson & Johnson, ImmunoPrecise, Novartis, AstraZeneca, Cipla, AbbVie, Bayer, Regeneron Pharmaceuticals, Ascletis Pharma, GlaxoSmithKline, Gilead Sciences, Pharmstandard, Fujifilm Holdings, Zhejiang Hisun Pharmaceutical Co. Ltd, Roche, Sanofi, and Pfizer holding significant market shares. These companies are engaged in extensive research and development, strategic collaborations, and acquisitions to maintain their competitive positions. Moreover, the emergence of biosimilars and the potential availability of generic versions of COVID-19 treatments are expected to intensify competition in the market.

  2. The Health Protection (Coronavirus, Restrictions) (Steps etc.) (England)...

    • gov.uk
    • s3.amazonaws.com
    Updated Jul 13, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Department of Health and Social Care (2022). The Health Protection (Coronavirus, Restrictions) (Steps etc.) (England) (Revocation and Amendment) Regulations 2021: equality analysis [Dataset]. https://www.gov.uk/government/publications/the-health-protection-coronavirus-restrictions-steps-etc-england-revocation-and-amendment-regulations-2021-equality-analysis
    Explore at:
    Dataset updated
    Jul 13, 2022
    Dataset provided by
    GOV.UKhttp://gov.uk/
    Authors
    Department of Health and Social Care
    Description

    These documents record the equality analysis undertaken for the decision to move England into step 4 through the Health Protection (Coronavirus, Restrictions) (Steps etc.) (England) (Revocation and Amendment) Regulations 2021.

    Ministers are required under the https://www.legislation.gov.uk/uksi/2011/2260/contents/made">Public Sector Equality Duty (PSED) as set out in section 149 of the Equality Act 2010 to have regard to the need to:

    • eliminate unlawful discrimination, harassment and victimisation
    • advance equality of opportunity between different groups
    • foster good relations between different groups

    Ministers are required to consider the impact of policy decisions on people’s protected characteristics, with particular emphasis on meeting the duties set out above. These protected characteristics are:

    • age
    • disability
    • gender reassignment
    • pregnancy and maternity
    • marriage and civil partnership
    • race
    • religion or belief
    • sex
    • sexual orientation

    The regulations covered by these PSED documents relate to the decision to move England into step 4 on 19 July 2021. This resulted in most legal restrictions, including those relating to social distancing and social contact, ending. All remaining businesses were allowed to reopen.

  3. C

    COVID 19 Diagnostics Market Report

    • promarketreports.com
    doc, pdf, ppt
    Updated Feb 4, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Pro Market Reports (2025). COVID 19 Diagnostics Market Report [Dataset]. https://www.promarketreports.com/reports/covid-19-diagnostics-market-6155
    Explore at:
    ppt, doc, pdfAvailable download formats
    Dataset updated
    Feb 4, 2025
    Dataset authored and provided by
    Pro Market Reports
    License

    https://www.promarketreports.com/privacy-policyhttps://www.promarketreports.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The size of the COVID 19 Diagnostics Market was valued at USD 81 billion in 2023 and is projected to reach USD 139.18 billion by 2032, with an expected CAGR of 8.04% during the forecast period. Recent developments include: May 2020 Bio-Rad Laboratories, Inc. Bio-Rad received FDA Emergency Use Authorization (EUA) for Droplet Digital PCR SARS-CoV-2 Test Kit for the detection of COVID-19., May 2020 F. Hoffmann-La Roche Ltd Roche received emergency use authorization (EUA) from the US FDA for the Elecsys Anti-SARS-CoV-2 antibody test for the detection of COVID-19., April 2020 Becton, Dickinson, and Company received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). It uses in diagnosing the patients infected with COVID-19.. Key drivers for this market are: INCREASING NUMBER OF COVID-19 CASES 26, GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26; RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26; DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27. Potential restraints include: RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28, ACCURACY OF TEST RESULTS 28. Notable trends are: Rising prevalence of coronavirus disease.

  4. Reported road casualties Great Britain, annual report: 2023

    • gov.uk
    Updated Sep 26, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Department for Transport (2024). Reported road casualties Great Britain, annual report: 2023 [Dataset]. https://www.gov.uk/government/statistics/reported-road-casualties-great-britain-annual-report-2023
    Explore at:
    Dataset updated
    Sep 26, 2024
    Dataset provided by
    GOV.UKhttp://gov.uk/
    Authors
    Department for Transport
    Area covered
    United Kingdom, Great Britain
    Description

    Our statistical practice is regulated by the Office for Statistics Regulation (OSR). OSR sets the standards of trustworthiness, quality and value in the Code of Practice for Statistics that all producers of official statistics should adhere to. You are welcome to contact us directly by emailing us with any comments about how we meet these standards.

    These are the final statistics on road collisions and casualties for Great Britain in 2023.

    Between 2022 and 2023, there was a small decline in reported road casualties in Great Britain with casualty numbers broadly following the trends observed before the COVID-19 pandemic. The number of fatalities in 2023 is the lowest recorded outside of years affected by the COVID-19 pandemic, although fatality figures are relatively small and can fluctuate from year to year. Overall casualties have returned to the steady decline observed prior to the COVID-19 pandemic, though the number of killed or seriously injured casualties has fallen less, particularly since 2017.

    In reported road collisions in Great Britain in 2023, there were an estimated:

    • 1,624 fatalities, a decline of 5% compared to 2022
    • 29,711 killed or seriously injured (KSI) casualties, little change compared to 2022
    • 132,977 casualties of all severities, a decline of 2% compared to 2022
    • 5 road fatalities per billion vehicle miles travelled, down 7% compared to 2022

    Alongside the main publication and full set of detailed road safety statistical tables, we have also published a range of road safety factsheets focussed on specific road users or topics, including the official statistics on e-scooter collisions and casualties, and new analyses looking at the ‘fatal 4’ factors based on the new road safety factors classification, and self-reported driver behaviour based on Crime Survey for England and Wales data.

    We have also published an update on progress in implementing the latest STATS19 review and future development roadmap, as well as new tools to download and to map casualty data.

    The next reported road casualty statistics, for the year to end June 2024, are scheduled for publication in November.

    Contact us

    Road safety statistics

    Email mailto:roadacc.stats@dft.gov.uk">roadacc.stats@dft.gov.uk

    To hear more about DfT statistical publications as they are released, follow us on X at https://x.com/dftstats?lang=en">DfTstats.

  5. Not seeing a result you expected?
    Learn how you can add new datasets to our index.

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
Data Insights Market (2025). covid 19 treatment Report [Dataset]. https://www.datainsightsmarket.com/reports/covid-19-treatment-1494332

covid 19 treatment Report

Explore at:
17 scholarly articles cite this dataset (View in Google Scholar)
ppt, doc, pdfAvailable download formats
Dataset updated
Jan 7, 2025
Dataset authored and provided by
Data Insights Market
License

https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy

Time period covered
2025 - 2033
Area covered
CA
Variables measured
Market Size
Description

The global COVID-19 treatment market, valued at USD 59.2 million in 2025, is projected to reach USD 329.1 million by 2033, exhibiting a CAGR of 25.1% during the forecast period. The significant growth can be attributed to the rising prevalence of COVID-19, increasing government initiatives, and ongoing research and development activities in the development of novel treatments. Additionally, the growing demand for antiviral drugs and monoclonal antibodies, as well as supportive therapies, is further fueling market growth. The market is highly competitive, with prominent players such as Cadila Healthcare, Johnson & Johnson, ImmunoPrecise, Novartis, AstraZeneca, Cipla, AbbVie, Bayer, Regeneron Pharmaceuticals, Ascletis Pharma, GlaxoSmithKline, Gilead Sciences, Pharmstandard, Fujifilm Holdings, Zhejiang Hisun Pharmaceutical Co. Ltd, Roche, Sanofi, and Pfizer holding significant market shares. These companies are engaged in extensive research and development, strategic collaborations, and acquisitions to maintain their competitive positions. Moreover, the emergence of biosimilars and the potential availability of generic versions of COVID-19 treatments are expected to intensify competition in the market.

Search
Clear search
Close search
Google apps
Main menu